重度哮喘诊治新进展  

Diagnosis and treatment of severe asthma:an update

作　　者：倪灏然 樊剑 朱星星 商艳[1,2] NI Haoran;FAN Jian;ZHU Xingxing;SHANG Yan(Department of Respiratory and Critical Care Medicine,The First Affiliated Hospital of Naval Medical University(Second Military Medical University),Shanghai 200433,China;Department of General Practice,The First Affiliated Hospital of Naval Medical University(Second Military Medical University),Shanghai 200433,China;Department of Respiratory and Critical Care Medicine,Haining People’s Hospital,Haining 314400,Zhejiang,China)

机构地区：[1]海军军医大学(第二军医大学)第一附属医院呼吸与危重症医学科,上海200433 [2]海军军医大学(第二军医大学)第一附属医院全科医学科,上海200433 [3]海宁市人民医院呼吸与危重症医学科,海宁314400

出　　处：《海军军医大学学报》2024年第11期1327-1335,共9页Academic Journal of Naval Medical University

基　　金：国家自然科学基金(82170033);海军军医大学(第二军医大学)第一附属医院破浪创新人才计划;上海市“社区医学与健康管理科研课题研究”专项基金(2023SQ01);上海市虹口区卫生健康委员会医学科研课题(虹卫2302-43);浙江省基础公益研究计划项目(LQ22H010001)。

摘　　要：重度哮喘在总体哮喘人群中占比为5%~10%,导致患者生活质量显著下降、医疗支出明显增加。尽管目前对重度哮喘患者给予高剂量吸入性糖皮质激素联合长效β_(2)受体激动剂或口服糖皮质激素治疗,但仍有部分患者难以控制症状,且长期大量使用激素会带来许多不良反应。近年来针对重度哮喘的诊断和治疗手段不断进步,为临床应用提供了很多新选择。本文就重度哮喘的病情评估、生物制剂治疗、经支气管镜介入治疗等方面的研究进展进行综述。Severe asthma accounts for 5%-10%of the overall asthma population,resulting in a substantial decline in patients’quality of life and a significant financial burden.Despite there are some treatment options,such as combining high-dose inhaled corticosteroids with long-actingβ_(2)agonists or oral corticosteroids,some patients continue to struggle with symptom control;in addition,prolonged steroid use can lead to various adverse effects.Recent years have witnessed continuous advancements in the diagnosis and treatment approaches for severe asthma,offering clinicians numerous novel alternatives.This article reviews their research progress encompassing disease assessment,medication therapy,and bronchoscopic interventions.

关 键 词：重度哮喘 呼吸系统疾病 分子靶向治疗 肺部成像技术 支气管热成型术 

分 类 号：R562.25[医药卫生—呼吸系统]